TAPHCO was established in the year 2000 in Algeria, commencing commercial production in 2017 of selected drugs covering various therapeutic segments under TAPHCO trademarks. The company also does contracted productions for SPIMACO to manufacture and produce some of SPIMACO’s agreed upon drugs. TAPHCO also purchased production files from distinguished international pharmaceutical companies, while enjoying high revenues in the Algerian Market. The company’s capital is nearly DZD 1.083 Billion, of which ACDIMA owns 28.98%. TAPHCO has a manufacturing unit built according to international standards in terms of good manufacturing practices, particularly in the areas of production, quality assurance, quality control and environmental performance. TAPHCO's short-term ambition is to make its factory a reference manufacturing site and to bring out from its culture the search for the highest level of performance. Its main activities will be: Manufacturing for human use and marketing in Algeria of TAPHCO specialties; The manufacture for human use and the marketing in Algeria of the specialties of the partners; Product shaping service at the request of partners and others.